UBE2O as a key regulator of drug-induced erythropoiesis in the context of myelodysplastic syndromes.

However, patients with lower-risk MDS who responded to luspatercept showed a trend of upregulation of expression of UBE2O and GATA1 ( Figure 4 A-B).

also in 53,322 other papers